Feb 21, 2013 by Dan CarrollIsis Pharmaceuticals Launches Trial, Hits MilestoneCompany to receive $7.5 million milestone payment for launching phase 2/3 study.
Feb 21, 2013 by Dan CarrollActivision Blizzard Announces "Diablo 3" for Sony Game ConsolesCompany looking to expand audience for game that has sold more than 12 million PC copies worldwide
Feb 21, 2013 by Dan CarrollIBM Launches New Mobile PortfolioCompany's MobileFirst designed with business and cloud-based solutions in mind.
Feb 21, 2013 by Dan CarrollPan American Silver Boosts Silver Reserves 35%Company discovered more than 31.2 million proven and probable reserves in 2012.
Feb 21, 2013 by Dan CarrollGilead, Teva Agree to End Patent FeudCompanies craft settlement in fight over patent rights to Viread.
Feb 21, 2013 by Dan CarrollHow the FOMC Sent the Dow SlidingThe FOMC's release of minutes sent investors scurrying in retreat.
Feb 21, 2013 by Dan CarrollThe Not-So-Hip Trend at Johnson & JohnsonHealth care's biggest player is taking heat for hip implant recalls
Feb 20, 2013 by Dan CarrollCan Abbott Grow This Global Business?Abbott's generic drug business records strong sales, but what does the future hold?
Feb 20, 2013 by Dan CarrollITC Reviewing Apple's Patent Victory Over MotorolaCommission to review judge's decision to invalidate Motorola Mobility patents
Feb 20, 2013 by Dan CarrollCaterpillar's Earnings Weigh Down the DowShares of the industrial giant fall to lead all index laggards.
Feb 20, 2013 by Dan CarrollRaytheon Ready to Produce New Precision ArtilleryCompany receives $56.6 million contract from U.S. Army.
Feb 20, 2013 by Dan CarrollEurope, CRM Woes Can't Subdue Medtronic's EarningsInvestors took the stock down, but there's no need to fret the company's progress
Feb 19, 2013 by Dan CarrollWill the Payroll Tax Hike Cripple the Recovery?Retailers fret as sales disappoint, but is the payroll tax holiday expiration that bad?
Feb 19, 2013 by Dan CarrollGE and Bank of America Surge as the Dow RisesAlcoa and UnitedHealth pace the laggards.
Feb 19, 2013 by Dan CarrollRoche Purchases Commercial Rights to Phase 3 DrugRoche paying up to $595 million to develop, market Chiasma's rare-disease drug Octreolin.
Feb 19, 2013 by Dan CarrollSt. Jude Launches Broad Renal Denervation StudyCompany looking to determine treatment effect on heart attack, stroke.
Feb 19, 2013 by Dan CarrollRaytheon, Chemring Developing Naval Defense SystemCompanies looking to produce naval capability to protect against surface threats.
Feb 15, 2013 by Dan CarrollThe G7 Strikes Back Against the YenStatements from the meeting halt the yen's weak streak, as Japan pushes market gains
Feb 15, 2013 by Dan CarrollPembina Pipeline Advancing on Peace Pipeline ExpansionCompany looking to expand capacity by 55,000 barrels per day.
Feb 15, 2013 by Dan CarrollMylan Announces Strategic Partnership with BioconAgreement expands upon past ties between companies; allows Mylan marketing rights to Biocon generic drugs
